ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

This study has been completed.

Sponsored by: Parexel
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier: NCT00002347
  Purpose

To evaluate the tolerance and immunologic and virologic effects of multidrug combinations of antiretrovirals in patients with HIV infection. Specifically, to evaluate zidovudine/zalcitabine ( AZT / ddC ) alone or in combination with either nevirapine or saquinavir ( Ro 31-8959 ).

Administration of three-drug combinations for treatment of HIV infection is preferred over monotherapy or duotherapy. A system has been designed to rapidly evaluate current multidrug combinations of antiretrovirals and allow the addition of new agents as they become available.


Condition Intervention Phase
HIV Infections
Drug: Saquinavir
Drug: Nevirapine
Drug: Zidovudine
Drug: Zalcitabine
Phase II

MedlinePlus related topics:   AIDS   

Drug Information available for:   Zidovudine    Zalcitabine    Nevirapine    Saquinavir    Saquinavir mesylate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Double-Blind, Efficacy Study
Official Title:   A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection: Retrovir/HIVID/Nevirapine and Retrovir/HIVID/Invirase

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment:   225

Detailed Description:

Administration of three-drug combinations for treatment of HIV infection is preferred over monotherapy or duotherapy. A system has been designed to rapidly evaluate current multidrug combinations of antiretrovirals and allow the addition of new agents as they become available.

Patients are randomized to receive AZT/ddC either alone or in combination with nevirapine or Ro 31-8959 for a minimum of 48 weeks. Patients are followed at weeks 2 and 4 and every 4 weeks thereafter.

  Eligibility
Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

Concurrent Medication:

Encouraged:

  • PCP chemoprophylaxis for patients whose CD4 count falls below 200 cells/mm3 or who develop PCP on study.

Allowed:

  • Secondary prophylaxis with nonexperimental agents in patients who develop TB, Mycobacterium avium-intracellulare, toxoplasmosis, histoplasmosis, cryptococcosis, disseminated candidiasis, or cytomegalovirus infection.
  • Acyclovir for 21 days or less for acute treatment.
  • Recombinant erythropoietin and G-CSF for grade 3 or worse anemia and neutropenia, respectively.

Patients must have:

  • HIV infection.
  • CD4 count 200 - 500 cells/mm3.
  • No prior antiretroviral therapy.
  • Life expectancy of at least 48 weeks.
  • Consent of parent or guardian if less than 18 years of age.

NOTE:

  • Participating centers are encouraged to enroll female patients.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Any grade 3 or greater toxicity.
  • Symptoms of peripheral neuropathy.
  • Malabsorption or severe chronic diarrhea.
  • Inability to eat at least one meal daily because of chronic nausea, emesis, or abdominal or esophageal discomfort.

Concurrent Medication:

Excluded during the first 28 days of nevirapine administration:

  • Augmentin and other antibiotics containing clavulanic acid.

Excluded at any time:

  • Dicumarol, warfarin, and other anticoagulant medications.
  • Tolbutamide.
  • Cimetidine.
  • Erythromycin.

Patients with the following prior conditions are excluded:

  • History of acute or chronic pancreatitis.
  • History of grade 2 or worse peripheral neuropathy from any cause.

Prior Medication:

Excluded:

  • Any prior antiretroviral therapy.

Excluded within 4 weeks prior to study entry:

  • Immunomodulating agents such as systemic corticosteroids, IL-2, alpha-interferon, beta-interferon, or gamma-interferon.
  • Immunotherapeutic vaccines.
  • Cytotoxic chemotherapy.
  • Erythromycin.
  • Dicumarol, Coumadin / warfarin, and other anticoagulant medications.
  • Phenobarbital.
  • Amoxicillin / clavulanate.
  • Ticarcillin / clavulanate.
  • Tolbutamide.
  • Erythromycin.
  • Cimetidine.

Prior Treatment:

Excluded within 4 weeks prior to study entry:

  • Non-local radiation therapy. Current alcohol or illicit drug use that would interfere with ability to comply with study requirements.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002347

Locations
United States, Massachusetts
PAREXEL Intl Corp / InterCo Collaboration Ctr    
      Waltham, Massachusetts, United States, 02154

Sponsors and Collaborators
Parexel
  More Information


Publications:
Thompson M, Myers M, Salgo M, Rousseau F, Odorisio M, Warburg M. A master protocol to evaluate the safety and efficacy of multidrug combination antiretroviral therapy with zidovudine and zalcitabine with or without saquinavir or nevirapine for the treatment of HIV infection. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:109 (abstract no 242)
 

Study ID Numbers:   229C, ICC 001
First Received:   November 2, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00002347
Health Authority:   United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Zalcitabine  
Drug Therapy, Combination  
Acquired Immunodeficiency Syndrome  
AIDS-Related Complex  
Zidovudine
Nevirapine
Saquinavir

Study placed in the following topic categories:
Virus Diseases
Nevirapine
Sexually Transmitted Diseases, Viral
Saquinavir
HIV Infections
Zalcitabine
Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
Zidovudine
AIDS-Related Complex
Retroviridae Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:
Antimetabolites
Anti-Infective Agents
Communicable Diseases
HIV Protease Inhibitors
RNA Virus Infections
Anti-HIV Agents
Slow Virus Diseases
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Infection
Antiviral Agents
Pharmacologic Actions
Protease Inhibitors
Reverse Transcriptase Inhibitors
Anti-Retroviral Agents
Therapeutic Uses
Lentivirus Infections
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers